Edison Expands North American Healthcare Sector Coverage with ADR Report on MorphoSys
LONDON, August 16, 2013 /PRNewswire/ –
Edison Investment Research, a leading international investment research firm,
announces the initiation of research coverage on the US-listed ADRs of MorphoSys (NASDAQ:
MPSYY), a German biotech company developing human antibodies for therapeutic use.
The ADR initiation follows two landmark licensing deals struck with GlaxoSmithKline
and Celgene that mark a transformation of the company. Edison’s comprehensive report
examines the investment merits of MorphoSys and derives a valuation of $1,895m, equivalent
to $39.70/ADR. MorphoSys has three proprietary programs and 16 programs from antibody
alliances in clinical development. It also has a 10-year alliance with Novartis. For the
full report see: http://www.edisoninvestmentresearch.com/research/company/morphosys
The launch of ADR coverage on MorphoSys is part of a programme of ADR research
initiations on foreign-domiciled, US-listed biotech companies, which are specifically
tailored for US investors. Edison will continue to provide research coverage in parallel
on the Frankfurt-listed shares of MorphoSys.
Edison provides research coverage on more than 130 healthcare companies in Europe,
North America and Australia. Edison has pioneered a scientific, detail-oriented approach
to analysing companies in the healthcare sector that is delivered in a concise and
non-promotional manner. It aims to inform investors, while providing a realistic
assessment of the competitive strengths and threats to key drug development programmes.
All facts are carefully sourced and the analysis is underpinned by comprehensive and
rigorous financial models. Edison’s reports provide an overall company valuation without
any specific stock recommendation.
All reports published by Edison are available to download free of charge from its
About Edison Investment Research
Edison, the investment intelligence firm, is the future of investor interaction with
corporates. Our team of over 100 analysts and investment professionals works with leading
companies, fund managers and investment banks worldwide to support its capital markets
activity. We provide services to more than 400 retained corporate and investor clients
from our offices in London, New York, Berlin, Sydney and Wellington. Edison is authorised
and regulated by the Financial Services Authority (
Edison is not an adviser or broker-dealer and does not provide investment advice.
Edison’s reports are not solicitations to buy or sell any securities.
MorphoSys developed HuCAL, the most successful antibody library technology in the
pharmaceutical industry. By successfully applying this and other patented technologies,
MorphoSys has become a leader in the field of therapeutic antibodies, one of the
fastest-growing drug classes in human healthcare. Together with its pharmaceutical
partners, MorphoSys has built a therapeutic pipeline [http://www.morphosys.com/pipeline ]
of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis and Alzheimer’s disease, to name just a few. With its ongoing commitment to new
antibody technology and drug development, MorphoSys is focused on making the healthcare
products of tomorrow.
For more information please contact: Dr Mick Cooper Edison Investment Research +44(0)20-3077-5734 firstname.lastname@example.org
SOURCE Edison Investment Research